309
Participants
Start Date
October 30, 2017
Primary Completion Date
March 31, 2026
Study Completion Date
December 31, 2026
HER3-DXd (FL-DP)
HER3-DXd (frozen liquid drug product) consists of an antibody component (patritumab, U3-1287) covalently conjugated to a drug-linker (MAAA-1162a) containing a drug component (MAAA-1181a).
HER3-DXd (CTM-1 Lyo-DP)
HER3-DXd (lyophilized drug product) consists of an antibody component (patritumab, U3-1287) covalently conjugated to a drug-linker (MAAA-1162a) containing a drug component (MAAA-1181a) that was manufactured by the clinical manufacturing sites.
HER3-DXd (CTM-3 Lyo-DP)
HER3-DXd (lyophilized drug product) consists of an antibody component (patritumab, U3-1287) covalently conjugated to a drug-linker (MAAA-1162a) containing a drug component (MAAA-1181a) that was manufactured by the commercial manufacturing sites.
COMPLETED
Memorial Sloan-Kettering Cancer Center, New York
RECRUITING
Hospital General Universitario Gregorio Maranon (HGUGM), Madrid
RECRUITING
Clinica Universidad Navarra(Madrid), Madrid
RECRUITING
Hospital Ramón y Cajal, Madrid
RECRUITING
Hospital Universitario 12 de Octubre, Madrid
RECRUITING
Hospital Universitario Madrid Sanchinarro - Centro Integral Oncologico Clara Campal (CIOCC), Madrid
RECRUITING
Hospital Universitario Quirónsalud Madrid, Madrid
RECRUITING
Winship Cancer Institute of Emory University, Atlanta
RECRUITING
Clínica Universidad de Navarra (Pamplona), Pamplona
COMPLETED
Sarah Cannon Research Institute/Tennesse Oncology, Nashville
TERMINATED
Chung Shan Medical University Hospital, Taichung
WITHDRAWN
Karmanos Cancer Institute, Detroit
COMPLETED
Henry Ford Hospital, Detroit
RECRUITING
Oncology Consultants P.A., Houston
WITHDRAWN
Pacific Shores Medical Group, Long Beach
COMPLETED
City of Hope, Duarte
NOT_YET_RECRUITING
University of California San Diego, La Jolla
RECRUITING
Fred Hutchinson Cancer Center, Seattle
RECRUITING
Northwest Medical Specialties, Tacoma
RECRUITING
The Cancer Institute Hospital of Japanese Foundation for Cancer Research (JFCR), Tokyo
RECRUITING
Shizuoka Cancer Center, Shizuoka
RECRUITING
Kindai University Hospital, Osaka
COMPLETED
Massachusetts General Hospital, Boston
RECRUITING
Dana-Farber Cancer Institute, Boston
WITHDRAWN
NYU Langone Health - NYU Medical Oncology Associates, New York
RECRUITING
Gabrail Cancer Center (GCC) - Canton Facility, Canton
RECRUITING
University of Pittsburgh Medical Center (UPMC) - Hillman Cancer Center (University of Pittsburgh Cancer Institute (UPCI), Pittsburgh
RECRUITING
National Cancer Center Hospital East (NCCHE) - Kashiwa Campus, Kashiwa-Shi
RECRUITING
Kurume University - Kurume University Hospital - Respiratory Diseases Center, Kurume-Shi
RECRUITING
Netherlands Cancer Institute, Amsterdam
RECRUITING
Seoul National University Hospital, Seoul
COMPLETED
Asan Medical Center, Seoul
RECRUITING
Samsung Medical Center, Seoul
RECRUITING
NEXT Oncology - Hospital Quironsalud Barcelona, Barcelona
RECRUITING
Hospital Universitario Vall d'Hebron, Barcelona
RECRUITING
National Cheng Kung University Hospital, Tainan City
RECRUITING
National Taiwan University Hospital, Taipei
Lead Sponsor
Merck Sharp & Dohme LLC
INDUSTRY
Daiichi Sankyo
INDUSTRY